Clinical Trials
51 trialsSANGUINE
JaxBio Ltd
Preliminary Assessment of [18F]BL40 in PET/CT Scans
British Columbia Cancer Agency
A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
Ruijin Hospital
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.
Chinese PLA General Hospital
AEDV Registry of Primary Cutaneous Lymphoma
Fundación Academia Española de Dermatología
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma
Gilead Sciences
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
Gilead Sciences
MALYZOMA-II
University Hospital, Strasbourg, France
Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma
Nanjing Sanhome Pharmaceutical, Co., Ltd.
LCMALT
National Taiwan University Hospital
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Marginal Zone Lymphoma Cohort in Korea
Dong-A University Hospital
Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma
Trans Tasman Radiation Oncology Group
BOMB-THROW
Seoul National University Hospital
BMPB
Royal Marsden NHS Foundation Trust
Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma
National Taiwan University Hospital
Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT Lymphoma
National Taiwan University Hospital
First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL
National Health Research Institutes, Taiwan
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
Jichi Medical University
Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer
National Cancer Institute (NCI)
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
National Cancer Institute (NCI)
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
National Cancer Institute (NCI)
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
National Cancer Institute (NCI)
Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Beta Alethine in Treating Patients With Low-Grade Lymphoma
National Cancer Institute (NCI)
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
National Cancer Institute (NCI)
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
National Cancer Institute (NCI)
Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia
National Cancer Institute (NCI)
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma
Korea Cancer Center Hospital
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
Technical University of Munich
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
National Cancer Institute (NCI)
Host Dendritic Cells in Allograft Patients
Icahn School of Medicine at Mount Sinai
Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
Medical University of Vienna
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
National Cancer Institute (NCI)
PERLL
Heidelberg University
Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)